Compounded Semaglutide: Cost, Safety, and the FDA Debate

Compounded semaglutide contains the same active ingredient as brand-name Ozempic and Wegovy — the GLP-1 receptor agonist semaglutide. It activates GLP-1 receptors to suppress appetite, slow gastric emptying, and enhance insulin secretion. However, compounded versions are not manufactured under the same rigorous FDA-approved process as Novo Nordisk products. They are prepared by compounding pharmacies using bulk semaglutide sodium salt, which differs chemically from the semaglutide base used in FDA-approved products.

Compounded semaglutide is a version of the GLP-1 medication semaglutide that is prepared by compounding pharmacies rather than manufactured by Novo Nordisk. Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare copies of FDA-approved drugs when those drugs are on the FDA Drug Shortage List. Semaglutide was placed on the shortage list in 2022 due to overwhelming demand, which allowed 503A (patient-specific) and 503B (outsourcing facility) compounding pharmacies to legally produce compounded versions. These products are typically sold at a fraction of the cost of brand-name Ozempic or Wegovy, making them attractive to patients without adequate insurance coverage. However, compounded products are not FDA-approved and do not undergo the same rigorous testing for safety, efficacy, potency, and sterility.

The FDA's position on compounded semaglutide has evolved significantly. In October 2023, the FDA issued warnings about the risks of compounded semaglutide, noting adverse event reports including hospitalizations. In 2024, as Novo Nordisk worked to resolve the branded shortage, the FDA moved toward removing semaglutide from the shortage list. Once a drug is removed from the shortage list, compounding pharmacies lose the legal basis to produce copies under the shortage exemption. The FDA has taken enforcement action against compounders marketing semaglutide products that it considers illegal copies. Notably, the FDA has pointed out that most compounders use semaglutide sodium salt, which is a different molecular form than the semaglutide base used in Ozempic and Wegovy — meaning these are not exact copies of the FDA-approved drug.

The cost difference is the primary driver of demand for compounded semaglutide. Brand-name Wegovy has a list price of approximately $1,349 per month and Ozempic approximately $935 per month. Compounded semaglutide typically costs $150-$500 per month, depending on the pharmacy, dose, and whether the prescription includes additional compounds (some clinics add B12 or other vitamins). This 60-85% cost reduction makes GLP-1 therapy accessible to patients who cannot afford brand-name medications and lack adequate insurance coverage. However, the lower cost reflects the absence of the extensive clinical testing, manufacturing controls, and quality assurance systems that support FDA-approved products. Patients should weigh the cost savings against the uncertainty about product quality.

• Wegovy (brand): ~$1,349/month without insurance
• Ozempic (brand): ~$935/month without insurance
• Compounded semaglutide: ~$150-$500/month (cash pay)
• Novo Nordisk savings card: may reduce brand-name copays to $25-$500/month for commercially insured patients
• Eli Lilly Zepbound vials: ~$399-$549/month (tirzepatide alternative for cash-pay patients)

If you choose compounded semaglutide, verifying the legitimacy of the compounding pharmacy is critical. The two types of compounding pharmacies are 503A pharmacies (which fill individual patient prescriptions under state pharmacy board oversight) and 503B outsourcing facilities (which are registered with the FDA and subject to FDA inspections). A 503B facility offers more safety assurance because it must follow current good manufacturing practices (cGMP) and report adverse events to the FDA. You can verify a 503B facility on the FDA's outsourcing facility registry. For 503A pharmacies, check accreditation through the Pharmacy Compounding Accreditation Board (PCAB) and verify the pharmacy's license through your state board of pharmacy. Be cautious of online-only operations without verifiable physical addresses or proper licensing.

• Check the FDA Outsourcing Facility Registry for 503B pharmacies
• Verify state pharmacy board licensure for 503A pharmacies
• Look for PCAB accreditation as a quality indicator
• Ask for third-party potency and sterility testing results (certificates of analysis)
• Avoid pharmacies that do not require a valid prescription from a licensed provider
• Be wary of prices that seem significantly below the typical $150-$500 range

The primary safety concerns with compounded semaglutide relate to product quality, not the semaglutide molecule itself. Without FDA-approved manufacturing controls, there is risk of inconsistent dosing between batches (meaning one vial may be more or less potent than the label states), contamination from non-sterile compounding environments, and the use of semaglutide sodium salt which has different physicochemical properties than the semaglutide base in brand-name products. The FDA has documented adverse events specifically tied to compounded GLP-1 products, including hospitalizations from suspected dosing errors or contamination. Patients taking compounded semaglutide should monitor for any unusual injection site reactions, unexplained illness, or symptoms that differ from typical GLP-1 side effects, and report concerns to their prescriber and the FDA MedWatch program.